Trovafloxacin

Class: Fluoroquinolone

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Binds to type II topoisomerases, gyrase and topoisomerase IV and thus, inhibits DNA cleavage and ligation reactions. It kills bacterial cells by increasing the concentration of enzyme–DNA cleavage complexes, thereby inhibiting cell replication.
Description:	Synthetic 1,8-Naphthyridine
Institute where first reported:	Pfizer, USA
Year first mentioned:	1993
Highest developmental phase:	Approved by FDA in 1997
Development status:	Discontinued
Reason Dropped:	Hepatotoxicity

Chemical structure(s):
Canonical SMILES:	C1=C(C=C(C(=C1)N2C=C(C(=O)C3=C2N=C(C(=C3)F)N4C[C@H]5[C@@H](C4)C5N)C(=O)O)F)F
Isomeric SMILES:	C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
InChI:	InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16?
InChI Key:	WVPSKSLAZQPAKQ-SOSAQKQKSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/62959

External links:
Guide to Pharmacology:	trovafloxacin
Main Source:	https://www.sciencedirect.com/science/article/pii/073288939390076J?via%3Dihub
Citation:	https://pubmed.ncbi.nlm.nih.gov/9917076/